CN112040958A - 含肽调配物 - Google Patents

含肽调配物 Download PDF

Info

Publication number
CN112040958A
CN112040958A CN201980026908.0A CN201980026908A CN112040958A CN 112040958 A CN112040958 A CN 112040958A CN 201980026908 A CN201980026908 A CN 201980026908A CN 112040958 A CN112040958 A CN 112040958A
Authority
CN
China
Prior art keywords
formulation
peptide
individual
cancer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980026908.0A
Other languages
English (en)
Chinese (zh)
Inventor
K·坎迪
K·K·格林茨塔弗
R·玛格南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cohbar Inc
Original Assignee
Cohbar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohbar Inc filed Critical Cohbar Inc
Publication of CN112040958A publication Critical patent/CN112040958A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980026908.0A 2018-03-27 2019-03-27 含肽调配物 Pending CN112040958A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648746P 2018-03-27 2018-03-27
US62/648,746 2018-03-27
PCT/US2019/024331 WO2019191264A1 (en) 2018-03-27 2019-03-27 Peptide-containing formulations

Publications (1)

Publication Number Publication Date
CN112040958A true CN112040958A (zh) 2020-12-04

Family

ID=66103053

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980026908.0A Pending CN112040958A (zh) 2018-03-27 2019-03-27 含肽调配物

Country Status (11)

Country Link
US (1) US11517608B2 (https=)
EP (1) EP3773627A1 (https=)
JP (1) JP2021519321A (https=)
KR (1) KR20200139723A (https=)
CN (1) CN112040958A (https=)
AU (1) AU2019243724A1 (https=)
CA (1) CA3097341A1 (https=)
IL (1) IL277466A (https=)
MX (1) MX2020010085A (https=)
TW (1) TW202002996A (https=)
WO (1) WO2019191264A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
CN118236470A (zh) * 2024-03-29 2024-06-25 无锡市第二人民医院 MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
CN119241659A (zh) * 2024-10-08 2025-01-03 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113876929B (zh) * 2021-11-22 2024-02-23 中国人民解放军陆军军医大学 肽MOTS-c在制备治疗帕金森药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229023A (zh) * 2013-03-15 2016-01-06 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
CA3038292A1 (en) * 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076532A2 (en) 2000-04-11 2001-10-18 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US8309525B2 (en) 2007-05-30 2012-11-13 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
AU2008269954A1 (en) 2007-06-29 2009-01-08 Centocor Ortho Biotech Inc. Anti- MCP-1 antibodies, compositions, methods and uses
US7998928B2 (en) 2007-09-14 2011-08-16 The Regents Of The University Of California Method of treatment of type-1 diabetes with a humanin analogue
WO2009135165A2 (en) 2008-05-01 2009-11-05 The Regents Of The University Of California Small humanin-like peptides
WO2012009709A1 (en) 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US20130123168A1 (en) 2011-06-17 2013-05-16 The Regents Of The University Of California Humanin and humanin-analogues for the management of atherosclerosis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229023A (zh) * 2013-03-15 2016-01-06 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
CA3038292A1 (en) * 2016-09-28 2018-04-05 Cohbar, Inc. Therapeutic mots-c related peptides
CN110072883A (zh) * 2016-09-28 2019-07-30 科巴公司 治疗性mots-c相关的肽
US20200181197A1 (en) * 2016-09-28 2020-06-11 Cohbar, Inc. Therapeutic peptides
US20210363187A1 (en) * 2016-09-28 2021-11-25 Cohbar, Inc. Therapeutic peptides
US20220242912A1 (en) * 2016-09-28 2022-08-04 Cohbar, Inc. Therapeutic peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHANGHAN LEE 等: "MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism", 《FREE RADIC BIOL MED.》, 1 May 2016 (2016-05-01) *
CHANGHAN LEE 等: "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance", 《CELL METABOLISM》, 1 March 2015 (2015-03-01) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115444926A (zh) * 2022-05-10 2022-12-09 江南大学 MOTS-c肽及其衍生物在制备放射性肺损伤治疗药物中的应用
CN118236470A (zh) * 2024-03-29 2024-06-25 无锡市第二人民医院 MOTS-c肽及其衍生物在制备支气管哮喘治疗药物中的应用
CN119241659A (zh) * 2024-10-08 2025-01-03 西北大学 MOTS-c及其氨基酸突变多肽在伤口愈合方面的用途

Also Published As

Publication number Publication date
CA3097341A1 (en) 2019-10-03
US11517608B2 (en) 2022-12-06
JP2021519321A (ja) 2021-08-10
US20210030835A1 (en) 2021-02-04
AU2019243724A1 (en) 2020-10-29
KR20200139723A (ko) 2020-12-14
IL277466A (en) 2020-11-30
WO2019191264A1 (en) 2019-10-03
TW202002996A (zh) 2020-01-16
EP3773627A1 (en) 2021-02-17
MX2020010085A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
US5853748A (en) Pharmaceutical compositions
CN112040958A (zh) 含肽调配物
GB2487808A (en) Oral adjuvant or formulation comprising a lipid and an alcohol
AU2015275237B2 (en) Compositions and methods for treating joints
KR20240063866A (ko) 결정-연관 및 비-결정-연관 급성 관절염의 치료에 사용하기 위한 콜히친을 포함하는 관절내 주사를 위한 투여 형태
US11771708B2 (en) Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
CN118370728A (zh) 一种glp-1ra载药纳米颗粒和制剂及其制备方法
US20220031612A1 (en) Uricase gel preparation for external use, preparation method therefor and use thereof
WO2016000637A1 (zh) 一种降血脂组合物及其应用
HK40039285A (zh) 含肽调配物
CN117603300A (zh) 具有二肽基肽酶-4抑制活性的小分子肽及其应用
US20150174208A1 (en) Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly
CN109260217A (zh) 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用
CN109718200B (zh) 一种水飞蓟素的复合物以及采用该复合物的水分散系
WO2013100793A1 (ru) Производное инсулина, обладающее сахароснижающей активностью, и способ его получения
CN104888201B (zh) 用于防治糖尿病及其慢性并发症的肽类药物
WO2025097049A1 (en) Rna-sn-38 conjugate for the treatment of colorectal cancer and sequential lung metastasis
Buchman Bile Acid Sequestrants
CN107412223A (zh) 一种含氧杂环化合物的医药用途
RU2402316C2 (ru) Фармацевтическая антиглаукомная композиция
WO2024089046A1 (en) Dosage form for intra-articular injection comprising colchicine and an anesthesic agent in the treatment of crystal-and non-crystal associated acute inflammatory arthritis
CN102120032B (zh) 一种适于制备博来霉素及其同系物水溶制剂的水溶基质
CN100560058C (zh) 一种口服、快速起效的镇痛药物
WO2015062158A1 (zh) 重组人睫状神经营养因子的鼻腔给药组合物及其制备方法
CN102935077A (zh) 仿生型洛伐他汀纳米脂质载体及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40039285

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201204

WD01 Invention patent application deemed withdrawn after publication